国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2013年
8期
634-638
,共5页
张慎锋%田涛%王文朋%王涛
張慎鋒%田濤%王文朋%王濤
장신봉%전도%왕문붕%왕도
乳腺肿瘤%药物疗法%预后
乳腺腫瘤%藥物療法%預後
유선종류%약물요법%예후
Breast neoplasms%Drug therapy%Prognosis
目的 探讨多西他赛联合吉西他滨治疗复发转移性乳腺癌的临床疗效及预后影响因素.方法 复发转移性乳腺癌患者46例,给予多西他赛联合吉西他滨治疗,具体方案为:多西他赛75 mg/m2,静脉滴注1h,第1天；吉西他滨1000 mg/m2,静脉滴注30 min,第1、8天；21 d为1个周期,评价患者近期疗效并随访患者总生存时间和无进展生存时间.采用单因素x2检验和多因素Cox风险比例模型分析患者临床病理特征与总有效率和总生存时间的关系.结果 46例复发转移性乳腺癌患者均接受3～6个周期的联合化疗治疗,完全缓解4例(8.7％),部分缓解22例(47.8％),稳定12例(26.1％),进展8例(17.4％),总有效率为56.5％ (26/46),疾病控制率为82.6％ (38/46)；中位总生存时间为16.0个月(95％ CI为6.5 ～25.5个月),中位无进展生存时间为8.0个月(95％ CI为6.2～9.8个月)；单因素分析结果显示,患者年龄、绝经状态、行为状况(PS)评分、肿瘤转移数目均与患者总有效率相关(P＜0.05),多因素Cox风险比例模型分析显示,患者年龄、绝经状态、PS评分、肿瘤转移数目均与患者的总生存时间相关,是患者预后的影响因素(P＜0.05)；主要不良反应以骨髓抑制、胃肠道反应、皮疹、脱发及乏力为主,大多数为Ⅰ～Ⅱ级.结论 多西他赛联合吉西他滨治疗复发转移性乳腺癌的临床疗效好,安全性高；患者年龄、绝经状态、PS评分、肿瘤转移数目可作为该方案预后的影响因素.
目的 探討多西他賽聯閤吉西他濱治療複髮轉移性乳腺癌的臨床療效及預後影響因素.方法 複髮轉移性乳腺癌患者46例,給予多西他賽聯閤吉西他濱治療,具體方案為:多西他賽75 mg/m2,靜脈滴註1h,第1天；吉西他濱1000 mg/m2,靜脈滴註30 min,第1、8天；21 d為1箇週期,評價患者近期療效併隨訪患者總生存時間和無進展生存時間.採用單因素x2檢驗和多因素Cox風險比例模型分析患者臨床病理特徵與總有效率和總生存時間的關繫.結果 46例複髮轉移性乳腺癌患者均接受3～6箇週期的聯閤化療治療,完全緩解4例(8.7％),部分緩解22例(47.8％),穩定12例(26.1％),進展8例(17.4％),總有效率為56.5％ (26/46),疾病控製率為82.6％ (38/46)；中位總生存時間為16.0箇月(95％ CI為6.5 ～25.5箇月),中位無進展生存時間為8.0箇月(95％ CI為6.2～9.8箇月)；單因素分析結果顯示,患者年齡、絕經狀態、行為狀況(PS)評分、腫瘤轉移數目均與患者總有效率相關(P＜0.05),多因素Cox風險比例模型分析顯示,患者年齡、絕經狀態、PS評分、腫瘤轉移數目均與患者的總生存時間相關,是患者預後的影響因素(P＜0.05)；主要不良反應以骨髓抑製、胃腸道反應、皮疹、脫髮及乏力為主,大多數為Ⅰ～Ⅱ級.結論 多西他賽聯閤吉西他濱治療複髮轉移性乳腺癌的臨床療效好,安全性高；患者年齡、絕經狀態、PS評分、腫瘤轉移數目可作為該方案預後的影響因素.
목적 탐토다서타새연합길서타빈치료복발전이성유선암적림상료효급예후영향인소.방법 복발전이성유선암환자46례,급여다서타새연합길서타빈치료,구체방안위:다서타새75 mg/m2,정맥적주1h,제1천；길서타빈1000 mg/m2,정맥적주30 min,제1、8천；21 d위1개주기,평개환자근기료효병수방환자총생존시간화무진전생존시간.채용단인소x2검험화다인소Cox풍험비례모형분석환자림상병리특정여총유효솔화총생존시간적관계.결과 46례복발전이성유선암환자균접수3～6개주기적연합화료치료,완전완해4례(8.7％),부분완해22례(47.8％),은정12례(26.1％),진전8례(17.4％),총유효솔위56.5％ (26/46),질병공제솔위82.6％ (38/46)；중위총생존시간위16.0개월(95％ CI위6.5 ～25.5개월),중위무진전생존시간위8.0개월(95％ CI위6.2～9.8개월)；단인소분석결과현시,환자년령、절경상태、행위상황(PS)평분、종류전이수목균여환자총유효솔상관(P＜0.05),다인소Cox풍험비례모형분석현시,환자년령、절경상태、PS평분、종류전이수목균여환자적총생존시간상관,시환자예후적영향인소(P＜0.05)；주요불량반응이골수억제、위장도반응、피진、탈발급핍력위주,대다수위Ⅰ～Ⅱ급.결론 다서타새연합길서타빈치료복발전이성유선암적림상료효호,안전성고；환자년령、절경상태、PS평분、종류전이수목가작위해방안예후적영향인소.
Objective To explore the efficacy and the prognostic factors of docetaxel combined with gemcitabine for patients with recurrent or metastatic breast cancer.Methods Forty-six patients with recurrent or metastatic breast cancer received docetaxel combined with gemcitabine regimen (docetaxel 75 mg/m2,intravenous drip,dl ; gemcitabine 1000 mg/m2,intravenous drip,dl,d8; The regimen was repeated every threeweeks for 3-6 cycles).The response rate (RR) was evaluated after 2 cycles,and the overall survival (OS)and progress-free survival (PFS) were recorded.Single factor chi square test and multivariate Cox proportion hazard model were used to evaluate the relationship between clinic pathologic features and RR,OS.Results All patients completed 3-6 cycls chemotherapy.The overall response rate was 56.5％ (26/46) and disease control rate was 82.6％ (38/46),with 4 patients of complete remission (8.7％),22 patients of partial remission (47.8％),12 patients of stable disease (26.1％) and 8 patients of progressive disease (17.4％).The median OS of 46 patients was 16.0 months (95％ CI:6.5-25.5 months) and PFS was 8.0 months (95％ CI:6.2-9.8 months).Single factor analysis showed that age,menopausal status,PS score,the number of metastasis had correhtions with RR (P ＜ 0.05) ; Cox proportion hazard model also showed that age,menopausal status,PS score,the number of metastasis had correlations with OS,and were the prognostic factors (P ＜0.05).The most frequent treatment-related adverse events were myelosuppression,gastrointestinal reaction,rash,alopecia,fatigue,and were tolerable (Ⅰ-Ⅱ level).Condusion Docetaxel combined with gemcitabine is effective and safe in the treatment of recurrent or metastatic breast cancer.Age,menopausal status,PS score and the number of metastasis are the prognostic factors for efficacy of docetaxel combined with gemcitabine regimen.
